TickerTalks
Browse all tickers →
TickerTalks›$VRTX
VRVRTX

Vertex Pharmaceuticals Incorporated

$VRTX·$121B·Biotechnology·Healthcare
$528.19+2.5%YTD+5.4%1Y+35.5%
Mentions · last 7 days
2026-08-12: 10 posts2026-08-13: 10 posts2026-08-14: 12 posts2026-08-15: 11 posts2026-08-16: 5 posts2026-08-17: 7 posts2026-08-18: 15 posts70+4%
Price updated 14h ago·X counts updated 12h ago
VRVRTX
$VRTXVertex Pharmaceuticals Incorporated
$528.19+2.45%70 posts+4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $VRTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-19

The move is getting stronger, with heavier trading behind it.

Cystic-fibrosis monopoly widens as Sionna halts its Phase 2a — VRTX +5.6% on the read-through.

Vertex Pharmaceuticals runs the effective monopoly in cystic-fibrosis therapy (Trikafta franchise) and is diversifying into pain (Journavx), sickle-cell (Casgevy with CRISPR), and Type 1 diabetes. Tape at $528.19 (+2.5% today), +5% YTD, +36% over twelve months, $121B cap.

  • Sionna Therapeutics halted its cystic-fibrosis Phase 2a after disappointing results — the fresh catalyst. VRTX jumped +5.6% on the read-through, KRYS also green.
  • The CF monopoly widens because Sionna was the credible near-term challenger; every year without a real competitor extends Trikafta's franchise value.
  • Fundamentals: PE 31.0x, PS 10.9x, gross margin 86%, operating margin 39%, ROIC 17.7%, ROE 24%.
  • Debt/equity 0.10 — clean balance sheet.
  • FCF yield 2.8% — reinvested into R&D, not payout.
  • Beta 0.31 — genuinely defensive.
  • Q1 revenue $2.99B EPS $4.06, Q4 $3.23B EPS $4.69.
  • All-time high hit August 14; Seeking Alpha rating upgrade 'I Was Wrong About Its Near-Term Prospects' — sell-side capitulation on the bear case.
  • November 2 Q3 print with $4.91 EPS consensus.

X is uniformly bullish and the specific chatter tracks the SION halt with market-appropriate framing ('you come at the king, you best not miss'). That's the correct read — Sionna's failure is a durable positive for VRTX because it removes a real competitive threat. The equity is priced for continued CF dominance plus optionality on Journavx/Casgevy/T1D. Real read: at 31x with a monopoly that just widened and a diversification pipeline maturing, the multiple has room if Q3 delivers.

Agrees with X sentimentX read is directionally right and specific — Sionna's Phase 2a halt is a genuine positive for the CF franchise. Nothing to disagree with on direction.

What to watch: November 2 Q3 print vs. $4.91 EPS bar, Trikafta franchise revenue, Journavx launch metrics, and Casgevy patient/payer uptake commentary.

On the calendar: Q3 earnings 2026-11-02

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-08-17

Vertex Pharmaceuticals chatter is uniformly bullish - VRTX gained +$27.84 (~+5.61%) to $523.91 after rival Sionna Therapeutics halted its cystic-fibrosis drug program following disappointing Phase 2a results, with KRYS also green on the read-through. Traders describe SION as always overhyped ('wasn't going to beat VRTX') and quote 'you come at the king, you best not miss'. Boulevard raising $65M for targeted autoimmune drugs is a peripheral watchlist item.

Read the AI verdict + X sentiment for $VRTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Dominates cystic fibrosis treatment with TRIKAFTA; expanding pipeline covers pain (non-opioid VX-548), APOL1 kidney disease, and type 1 diabetes.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $VRTX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $VRTX

Neutral — Dominates cystic fibrosis treatment with TRIKAFTA; expanding pipeline covers pain (non-opioid VX-548), APOL1 kidney disease, and type 1 diabetes; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+47.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
31.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
17.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
39.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
10.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
23.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
86.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 3, 2026$4.73$4.74-0.2%
Q1 2026May 4, 2026$4.47$4.24+5.4%
Q4 2025Feb 12, 2026$5.03$5.11-1.6%
Q3 2025Nov 3, 2025$4.80$4.57+5.0%
Next earningsMon, Nov 2·consensus EPS $4.91

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.0B+7.8%86.8%38.1%$4.06$1.3B
Q4 FY25$3.2B+10.8%85.6%40.3%$4.69$348.6M
Q3 FY25$3.1B+11.0%86.5%38.6%$4.24$1.1B
Q2 FY25$3.0B+12.1%86.3%38.8%$4.02$927.4M

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$13.1B$13.0B – $13.2B$19.23$18.87 – $19.7117
FY27$14.3B$13.5B – $16.1B$21.40$18.40 – $22.4816
FY28$16.0B$14.1B – $17.9B$25.39$20.50 – $34.0017
FY29$17.8B$17.0B – $19.2B$29.08$27.28 – $32.0114
FY30$19.6B$18.7B – $21.2B$33.22$31.17 – $36.588

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.90%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+9.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+15.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 253.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.305-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Ourania TatsisEVP, Chief Reg. & Quality Off.1.5K sh$787KSellJul 2Duncan MckechnieEVP, Chief Commercial Officer1.5K sh$800KSellJul 1Joy LiuEVP and Chief Legal Officer828 sh$416KSellJun 26Carmen BozicEVP and CMO596 sh$288KSellJun 18Carmen BozicEVP and CMO1.0K sh$471KSellJun 15Carmen BozicEVP and CMO4.1K sh$1.8MSellJun 5Carmen BozicEVP and CMO1.7K sh$785KSellMay 29Carmen BozicEVP and CMO2.0K sh$888KSellMay 15Mark E. BunnageEVP, Chief Scientific Officer33 sh$15KSellMay 15Carmen BozicEVP and CMO1.4K sh$614K
1–10 of 20
+ 20 other (16 awards · 4 returns) in window

See when $VRTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 78-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Vertex Pharmaceuticals Incorporated signed an Agreement and Plan of Merger on July 6, 2026 to acquire Crinetics Pharmaceuticals, Inc. in an all-cash deal at $85.00 per share, with Crinetics surviving as a wholly owned Vertex subsidiary. All outstanding unvested equity (options and RSUs) will accelerate and convert to the right to receive $85.00 (less any exercise price for options). Closing is subject to customary conditions. Transformative acquisition for Vertex, adding Crinetics' endocrine/rare disease pipeline to Vertex's portfolio at a significant cash premium — signals Vertex's intent to diversify beyond its core CF franchise.

8-KOfficer or director changeMay 138-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Vertex Pharmaceuticals held its 2026 Annual Meeting on May 13, 2026. Shareholders elected all 10 director nominees (including CEO Reshma Kewalramani, Jeffrey Leiden, Sangeeta Bhatia, and others) and approved the 2026 Stock and Option Plan, which replaces the 2013 plan. The new plan was approved by the Board on March 27, 2026. Vertex's strong governance and shareholder base typically result in routine approval of management proposals; the new equity plan provides incentive compensation capacity under an updated structure.

8-KOfficer or director changeApr 298-K — Item 5.02: Officer or director change
3New insider — initial holdingsMar 33
+ 24 other (7 S-8 POSs · 4 13Gs · 3 proxys · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNXgurufocus.com·2d agoCrinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNXbusinesswire.com·2d agoVertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even Morefool.com·5d agoVertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)seekingalpha.com·5d agoWhy Vertex Pharmaceuticals Stock Ticked Higher on Tuesdayfool.com·15d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$CAPR$ABCL$NWBO$AURA$SLS$ABVX$AMLX$IBRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport